MERS-CoV vaccine candidates in development: The current landscape

Vaccine

Volumn 34, Issue 26, 2016, Pages 2982-2987

  Modjarrad, Kayvon ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Coronavirus; Development; Middle East Respiratory Syndrome; Research; Vaccine

Indexed keywords

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS VACCINE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS ANTIBODY;

ARTICLE; CORONAVIRUS INFECTION; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOGENICITY; KNOWLEDGE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VACCINE PRODUCTION; VIRAL RESPIRATORY TRACT INFECTION; ANIMAL; CLINICAL TRIAL (TOPIC); CORONAVIRUS INFECTIONS; MEDICAL RESEARCH; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; TRENDS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CORONAVIRUS INFECTIONS; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; VIRAL VACCINES;

EID: 84963657815     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.03.104     Document Type: Article

References (57)

1. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367:1814-1820.
2. Hijawi B., Abdallat M., Sayaydeh A., Alqasrawi S., Haddadin A., Jaarour N., et al. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. East Mediterr Health J 2013, 19(Suppl 1):S12-S18.
3. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Summary and Literature Update-as of 11 June 2014 2014, WHO, World Health Organization, Geneva, Switzerland, [11 June].
4. Epidemiological Update: Middle East Respiratory Syndrome Coronavirus (MERS-CoV) 2014, ECDC, European Centre for Disease Prevention and Control, Stockholm, Sweden, [2 July].
5. Lee S.S., Wong N.S. Probable transmission chains of Middle East respiratory syndrome coronavirus and the multiple generations of secondary infection in South Korea. Int J Infect Dis 2015, 38:65-67.
6. Graham R.L., Donaldson E.F., Baric R.S. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 2013, 11:836-848.
7. Lelli D., Papetti A., Sabelli C., Rosti E., Moreno A., Boniotti M.B. Detection of coronaviruses in bats of various species in Italy. Viruses 2013, 5:2679-2689.
8. Wacharapluesadee S., Duengkae P., Rodpan A., Kaewpom T., Maneeorn P., Kanchanasaka B., et al. Diversity of coronavirus in bats from Eastern Thailand. Virol J 2015, 12:57.
9. Yang L., Wu Z., Ren X., Yang F., Zhang J., He G., et al. MERS-related betacoronavirus in Vespertilio superans bats, China. Emerg Infect Dis 2014, 20:1260-1262.
10. Alagaili A.N., Briese T., Mishra N., Kapoor V., Sameroff S.C., Burbelo P.D., et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio 2014, 5. e00884-00814.
11. Alexandersen S., Kobinger G.P., Soule G., Wernery U. Middle East respiratory syndrome coronavirus antibody reactors among camels in Dubai, United Arab Emirates, in 2005. Transbound Emerg Dis 2014, 61:105-108.
12. Corman V.M., Jores J., Meyer B., Younan M., Liljander A., Said M.Y., et al. Antibodies against MERS coronavirus in dromedary camels, Kenya, 1992-2013. Emerg Infect Dis 2014, 20:1319-1322.
13. Hemida M.G., Chu D.K., Poon L.L., Perera R.A., Alhammadi M.A., Ng H.Y., et al. MERS coronavirus in dromedary camel herd, Saudi Arabia. Emerg Infect Dis 2014, 20:1231-1234.
14. Azhar E.I., El-Kafrawy S.A., Farraj S.A., Hassan A.M., Al-Saeed M.S., Hashem A.M., et al. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 2014, 370:2499-2505.
15. Raj V.S., Osterhaus A.D., Fouchier R.A., Haagmans B.L. MERS: emergence of a novel human coronavirus. Curr Opin Virol 2014, 5:58-62.
16. Lu G., Hu Y., Wang Q., Qi J., Gao F., Li Y., et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013, 500:227-231.
17. Ohnuma K., Haagmans B.L., Hatano R., Raj V.S., Mou H., Iwata S., et al. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. J Virol 2013, 87:13892-13899.
18. Update: severe respiratory illness associated with Middle East respiratory syndrome coronavirus (MERS-CoV)-worldwide, 2012-2013. MMWR Morb Mortal Wkly Rep 2013, 62:480-483. Centers for Disease Control and Prevention.
19. de Wit E., Rasmussen A.L., Falzarano D., Bushmaker T., Feldmann F., Brining D.L., et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A 2013, 110:16598-16603.
20. Al-Tawfiq J.A., Assiri A., Memish Z.A. Middle East respiratory syndrome novel corona MERS-CoV infection. Epidemiology and outcome update. Saudi Med J 2013, 34:991-994.
21. Assiri A., Al-Tawfiq J.A., Al-Rabeeah A.A., Al-Rabiah F.A., Al-Hajjar S., Al-Barrak A., et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013, 13:752-761.
22. Falzarano D., de Wit E., Rasmussen A.L., Feldmann F., Okumura A., Scott D.P., et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013, 19:1313-1317.
23. Mair-Jenkins J., Saavedra-Campos M., Baillie J.K., Cleary P., Khaw F.M., Lim W.S., et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015, 211:80-90.
24. Kumar V., Jung Y.S., Liang P.H. Anti-SARS coronavirus agents: a patent review (2008-present). Expert Opin Ther Pat 2013, 23:1337-1348.
25. Wang L., Shi W., Joyce M.G., Modjarrad K., Zhang Y., Leung K., et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun 2015, 6:7712.
26. Du L., Kou Z., Ma C., Tao X., Wang L., Zhao G., et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 2013, 8:e81587.
27. Ma C., Li Y., Wang L., Zhao G., Tao X., Tseng C.T., et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine 2014, 32:2100-2108.
28. Tang J., Zhang N., Tao X., Zhao G., Guo Y., Tseng C.T., et al. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother 2015, 11:1244-1250.
29. Zhang N., Tang J., Lu L., Jiang S., Du L. Receptor-binding domain-based subunit vaccines against MERS-CoV. Virus Res 2015, 202:151-159.
30. Chen Y., Rajashankar K.R., Yang Y., Agnihothram S.S., Liu C., Lin Y.L., et al. Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J Virol 2013, 87:10777-10783.
31. Wang N., Shi X., Jiang L., Zhang S., Wang D., Tong P., et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013, 23:986-993.
32. Sui J., Deming M., Rockx B., Liddington R.C., Zhu Q.K., Baric R.S., et al. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness. J Virol 2014, 88:13769-13780.
33. Coleman C.M., Liu Y.V., Mu H., Taylor J.K., Massare M., Flyer D.C., et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 2014, 32:3169-3174.
34. Almazan F., DeDiego M.L., Sola I., Zuniga S., Nieto-Torres J.L., Marquez-Jurado S., et al. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. MBio 2013, 4. e00650-00613.
35. Song F., Fux R., Provacia L.B., Volz A., Eickmann M., Becker S., et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol 2013, 87:11950-11954.
36. Volz A., Kupke A., Song F., Jany S., Fux R., Shams-Eldin H., et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. J Virol 2015, 89:8651-8656.
37. Guo X., Deng Y., Chen H., Lan J., Wang W., Zou X., et al. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology 2015, 145:476-484.
38. Kim E., Okada K., Kenniston T., Raj V.S., AlHajri M.M., Farag E.A., et al. Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB/c mice. Vaccine 2014, 32:5975-5982.
39. Majumder M.S., Rivers C., Lofgren E., Fisman D. Estimation of MERS-coronavirus reproductive number and case fatality rate for the spring 2014 Saudi Arabia outbreak: insights from publicly available data. PLoS Curr 2014, 6. pii: ecurrents.outbreaks.98d2f8f3382d84f390736cd5f5fe133c. 10.1371/currents.outbreaks.98d2f8f3382d84f390736cd5f5fe133c.
40. Faure E., Poissy J., Goffard A., Fournier C., Kipnis E., Titecat M., et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?. PLoS One 2014, 9:e88716.
41. Jiang L., Wang N., Zuo T., Shi X., Poon K.M., Wu Y., et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 2014, 6(234):234ra59. 10.1126/scitranslmed.3008140.
42. Ying T., Du L., Ju T.W., Prabakaran P., Lau C.C., Lu L., et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol 2014, 88:7796-7805.
43. Tang X.C., Agnihothram S.S., Jiao Y., Stanhope J., Graham R.L., Peterson E.C., et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A 2014, 111:E2018-E2026.
44. Pascal K.E., Coleman C.M., Mujica A.O., Kamat V., Badithe A., Fairhurst J., et al. Pre- and postexposure efficacy of fully human antibodies against spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci U S A 2015, 112:8738-8743.
45. Corti D., Zhao J., Pedotti M., Simonelli L., Agnihothram S., Fett C., et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci U S A 2015, 112(33):10473-10478.
46. Abroug F., Slim A., Ouanes-Besbes L., Hadj Kacem M.A., Dachraoui F., Ouanes I., et al. Family cluster of Middle East respiratory syndrome coronavirus infections, Tunisia, 2013. Emerg Infect Dis 2014, 20:1527-1530.
47. Al-Abdallat M.M., Payne D.C., Alqasrawi S., Rha B., Tohme R.A., Abedi G.R., et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis 2014, 59:1225-1233.
48. Al-Tawfiq J.A., Hinedi K., Ghandour J., Khairalla H., Musleh S., Ujayli A., et al. Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin Infect Dis 2014, 59:160-165.
49. Assiri A., McGeer A., Perl T.M., Price C.S., Al Rabeeah A.A., Cummings D.A., et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013, 369:407-416.
50. Harriman K., Brosseau L., Trivedi K. Hospital-associated Middle East respiratory syndrome coronavirus infections. N Engl J Med 2013, 369:1761.
51. Memish Z.A., Al-Tawfiq J.A., Assiri A. Hospital-associated Middle East respiratory syndrome coronavirus infections. N Engl J Med 2013, 369:1761-1762.
52. Middleton D., Pallister J., Klein R., Feng Y.R., Haining J., Arkinstall R., et al. Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health. Emerg Infect Dis 2014, 20:372-379.
53. Middleton D. Hendra virus. Vet Clin N Am Equine Pract 2014, 30:579-589.
54. Haagmans B.L., van den Brand J.M., Raj V.S., Volz A., Wohlsein P., Smits S.L., et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 2015, 351(6268):77-81.
55. Zhao J., Li K., Wohlford-Lenane C., Agnihothram S.S., Fett C., Zhao J., et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A 2014, 111:4970-4975.
56. Agrawal A.S., Garron T., Tao X., Peng B.H., Wakamiya M., Chan T.S., et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 2015, 89:3659-3670.
57. van Doremalen N., Munster V.J. Animal models of Middle East respiratory syndrome coronavirus infection. Antivir Res 2015, 122:28-38.